The 150 most important questions in cancer research and clinical oncology series: questions 31–39Reportar como inadecuado

The 150 most important questions in cancer research and clinical oncology series: questions 31–39 - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Chinese Journal of Cancer

, 36:48

Edited by Chinese Journal of CancerFirst Online: 02 June 2017Received: 08 May 2017Accepted: 08 May 2017DOI: 10.1186-s40880-017-0215-6

Cite this article as: Chinese Journal of Cancer Chin J Cancer 2017 36: 48. doi:10.1186-s40880-017-0215-6


To accelerate our endeavors to overcome cancer, Chinese Journal of Cancer has launched a program of publishing 150 most important questions in cancer research and clinical oncology. In this article, 9 more questions are presented as follows. Question 31: How does aging process inhibit the formation of sarcoma? Question 32: Is intratumoral morphological heterogeneity the consequence of tumor genomic instability or the cause of aggressive tumor behavior? Can we identify more aggressive tumors by computationally analyzing the morphological heterogeneity of the tumor tissues? Question 33: How to pre-surgically differentiate irradiation-induced ulceration from cancerous ulceration? Question 34: Why is epidermal growth factor receptor EGFR 19 Del-positive tumor more sensitive to targeted therapy than EGFR 21 L858R-positive tumor in patients with non-small cell lung cancer? Question 35: Can an Epstein–Barr virus vaccine be developed to reduce the incidence of EBV-related malignancies? Question 36: What is the unique feature in sarcoma vasculature that causes the intrinsic resistance of sarcoma against anti-angiogenic therapy? Question 37: How many ways can sarcoma cells protect themselves from the attacks of cytotoxic drugs? Question 38: How stable does the tumor heterogeneity remain along with cytotoxic chemotherapy? Question 39: How to generate a prognostic classifier for diffuse low-grade gliomas by integrating genetic and epigenetic signatures with histological features?

KeywordsSarcoma Intratumoral morphological heterogeneity Pre-surgically differentiate irradiation-induced ulceration Epidermal growth factor receptor Non-small cell lung cancer Epstein–Barr virus-related malignancy Tumor heterogeneity Prognostic classifier Diffuse low-grade gliomas  Download fulltext PDF

Autor: Chinese Journal of Cancer


Documentos relacionados